News Releases

05/12/2008

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin® Clinical Trial in Acute Spinal Cord Injury

05/06/2008

Alseres Pharmaceuticals Enters Agreement to Amend Cethrin® License to Lower Milestone Payments and Royalty Rates

Upcoming Events

There are no events currently scheduled. Please check back soon.

At Alseres Pharmaceuticals, we're passionate about improving people's lives. We are a biopharmaceutical company focused on developing safe, innovative drugs using ground-breaking regenerative technologies targeted to traumatic injury and degenerative disease. Whether we're conducting clinical trials, collaborating with our business partners, or fostering physician and patient relationships, everyone at Alseres shares a commitment to find a better solution—and make it available to those who need it most.